Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 32
Eating disorder screens predict GLP-1 use
A US survey of 1,309 adults links positive eating disorder screens to higher GLP-1 awareness and telehealth drug-seeking.
GLP-1 drugs improve ratio but cut muscle
A 2026 meta-analysis of 7 RCTs finds GLP-1 receptor agonists raise the lean-to-fat ratio while causing a 1.74 kg average absolute lean mass loss.
GLP-1 drugs and lung safety: what we know
A 2026 systematic review examines pulmonary adverse events with GLP-1 receptor agonists, from mild upper-airway infections to perioperative aspiration risk.
Semaglutide tied to lower seizure risk
A target trial emulation using the All of Us database found semaglutide users had roughly half the seizure risk of adults on other glucose-lowering drugs.
Semaglutide may protect joints via muscle
A 2026 mouse study reports that semaglutide restores muscle mitochondrial function, raises glutamine, and reduces cartilage inflammation.
Semaglutide CV edge over tirzepatide
A 47-trial meta-analysis finds semaglutide cuts MACE by 29% and CV death by 19%. Tirzepatide trends protective but lacks the trial base to confirm it.
Semaglutide vs SGLT2 inhibitors in MASLD
A propensity-matched TriNetX study compares semaglutide against SGLT2 inhibitors in patients with fatty liver disease and type-2 diabetes.
Tirzepatide vs GLP-1s in spinal fusion
A 2026 retrospective study found tirzepatide users had fewer complications and revisions after spinal fusion than single-receptor GLP-1 agonist users.
Weight-loss drugs and fertility: the data
A meta-analysis of seven trials finds orlistat and semaglutide may boost ovulation and pregnancy rates in women with obesity.
BPC-157 side effects: what the data shows
BPC-157 has no approved label and no completed human safety trial. Here is what preclinical toxicology actually shows.
BPC-157 and anxiety: what the evidence says
Rodent studies suggest BPC-157 has anxiolytic effects. Human self-reports are mixed. No controlled human trial has measured anxiety as an outcome.
BPC-157 oral vs injectable for gut health
No human trial has compared oral BPC-157 tablets to reconstituted injectable for gut health. Here is what rodent data and the supply chain show.